MCID: PLY020
MIFTS: 46

Polyradiculoneuropathy

Categories: Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Polyradiculoneuropathy

MalaCards integrated aliases for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 11 53 43 14 16 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:4308
MeSH 43 D011129
SNOMED-CT 68 128078004
UMLS 71 C0032587

Summaries for Polyradiculoneuropathy

Disease Ontology: 11 A peripheral nervous system disease that is characterized by the co-occurance of polyneuropahty and polyradicuopathy and is located in both the spinal nerve roots and the peripheral nerves.

MalaCards based summary: Polyradiculoneuropathy is related to chronic inflammatory demyelinating polyradiculoneuropathy and guillain-barre syndrome. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are ERK Signaling and MIF Mediated Glucocorticoid Regulation. The drugs Immunoglobulin G and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, dorsal root ganglion and nk cells, and related phenotypes are normal and nervous system

Wikipedia: 75 Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur... more...

Related Diseases for Polyradiculoneuropathy

Diseases in the Polyradiculoneuropathy family:

Chronic Polyradiculoneuropathy

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 590)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyradiculoneuropathy 32.6 SH2D2A PMP22 MPZ MBP IFNG
2 guillain-barre syndrome 31.3 TNFRSF1A PMP22 PMP2 MPZ MBP IL17A
3 polyneuropathy 31.2 PMP22 MPZ MBP ALB
4 demyelinating polyneuropathy 31.0 PMP22 MPZ MBP ALB
5 hereditary neuropathies 30.6 PMP22 MPZ
6 roussy-levy hereditary areflexic dystasia 30.5 PMP22 MPZ
7 sensory peripheral neuropathy 30.4 PMP22 MPZ BDNF ALB
8 spinal cord disease 30.3 MBP IL10 ALB
9 autoimmune neuropathy 30.3 PMP2 MPZ IL10
10 myasthenia gravis 30.3 MBP IL10 IFNG HLA-DRB1
11 neuromuscular disease 30.3 PMP22 PMP2 MPZ MBP BDNF ALB
12 mononeuropathy 30.2 PMP22 MPZ ALB
13 charcot-marie-tooth disease, demyelinating, type 1a 30.2 PMP22 PMP2 MPZ MBP
14 autoimmune peripheral neuropathy 30.1 PMP2 MPZ
15 optic neuritis 30.1 MPZ MBP IL10 HLA-DRB1 BDNF
16 peroneal neuropathy 30.1 PMP22 MPZ
17 thyroiditis 30.1 IL10 IFNG HLA-DRB1
18 rubella 30.0 IL10 IFNG HLA-DRB1
19 churg-strauss syndrome 30.0 IL17A IL10 HLA-DRB1
20 neuromyelitis optica 30.0 MBP IL17A HLA-DRB1
21 severe acute respiratory syndrome 30.0 IL10 IFNG CCL5
22 radiculopathy 30.0 IL17A IL10 CCL5 CCL4
23 plexopathy 30.0 PMP22 MPZ
24 diabetic neuropathy 30.0 PMP22 MPZ BDNF ALB
25 neurosyphilis 30.0 IL17A IL10 BACE1
26 charcot-marie-tooth disease 29.9 PMP22 PMP2 MPZ MBP BDNF
27 rabies 29.9 HLA-DRB1 CCL5 ALB
28 myelitis 29.9 TNFRSF1A MBP IL17A IL10
29 hypertrophic neuropathy of dejerine-sottas 29.9 PMP22 MPZ MBP
30 cryoglobulinemia 29.9 IL10 IFNG HLA-DRB1
31 poliomyelitis 29.9 IL10 IFNG ALB
32 mixed connective tissue disease 29.9 IL10 IFNG HLA-DRB1
33 hepatitis e 29.8 IL10 IFNG ALB
34 chorioretinitis 29.8 IL17A IL10 IFNG
35 meningoencephalitis 29.8 MBP IL10 CCL5 BDNF ALB
36 chronic fatigue syndrome 29.8 IL10 IFNG BDNF
37 ileus 29.8 IL17A IL10 IFNG
38 sclerosing cholangitis 29.8 IL17A IL10 ALB
39 chlamydia 29.7 IL17A IL10 IFNG
40 castleman disease 29.7 IL10 IFNG CCL4
41 acquired immunodeficiency syndrome 29.7 TNFRSF1A MBP IL10 IFNG ALB
42 toxoplasmosis 29.7 IL17A IL10 IFNG
43 viral encephalitis 29.7 MBP IL10 CCL5
44 hepatitis a 29.7 IL10 IFNG HLA-DRB1 ALB
45 myositis 29.7 IL17A IFNG HLA-DRB1 BACE1
46 autoimmune disease 29.6 TNFRSF1A MBP IL17A IL10 IFNG HLA-DRB1
47 type 1 diabetes mellitus 29.6 IL17A IL10 IFNG HLA-DRB1 ALB
48 aseptic meningitis 29.6 NLRP3 IL10 ALB
49 brucellosis 29.6 NLRP3 IL17A IL10 IFNG
50 purpura 29.6 IL17A IL10 IFNG HLA-DRB1

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to Polyradiculoneuropathy

Symptoms & Phenotypes for Polyradiculoneuropathy

GenomeRNAi Phenotypes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.1 ALB BACE1 BDNF CCL19 CCL4 CCL5
2 no effect GR00402-S-2 10.1 ALB BDNF CCL19 CCL4 CCL5 CXCL12

MGI Mouse Phenotypes related to Polyradiculoneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.92 ALB BACE1 BDNF CXCL12 IFNG IL10
2 nervous system MP:0003631 9.9 BACE1 BDNF CXCL12 IFNG IL10 MBP
3 no phenotypic analysis MP:0003012 9.8 BACE1 BDNF CXCL12 IFNG IL10 IL17A
4 cellular MP:0005384 9.7 ALB BACE1 BDNF CXCL12 IFNG IL10
5 immune system MP:0005387 9.4 ALB CCL19 CCL5 CXCL12 IFNG IL10

Drugs & Therapeutics for Polyradiculoneuropathy

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulin G Phase 4
2
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
3
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
4 Immunoglobulins, Intravenous Phase 3
5 Immunoglobulins Phase 3
6 Antibodies Phase 3
7 gamma-Globulins Phase 3
8 Rho(D) Immune Globulin Phase 3
9 Immunologic Factors Phase 3
10
Fingolimod Hydrochloride Phase 3 162359-56-0
11 Hormones Phase 3
12 Hormone Antagonists Phase 3
13 Antineoplastic Agents, Hormonal Phase 3
14 glucocorticoids Phase 3
15 Anti-Inflammatory Agents Phase 3
16 Pharmaceutical Solutions Phase 2, Phase 3
17
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3
18
Melphalan Approved Phase 2 148-82-3 4053 460612
19
Carmustine Approved, Investigational Phase 2 154-93-8 2578
20
Etoposide Approved Phase 2 33419-42-0 36462
21
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
22
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
23
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
24
Rituximab Approved Phase 2 174722-31-7
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 253 171548
27
Lipoic acid Approved, Investigational, Nutraceutical Phase 2 1200-22-2 864 6112
28
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
29
Cortisone Experimental Phase 2 53-06-5 222786
30 Autoantibodies Phase 2
31 Adjuvants, Immunologic Phase 2
32 interferons Phase 2
33 Interferon-beta Phase 2
34 Folate Phase 2
35 Vitamins Phase 2
36 Vitamin B9 Phase 2
37 Vitamin B7 Phase 2
38 Trace Elements Phase 2
39 Vitamin B Complex Phase 2
40 Micronutrients Phase 2
41 Alpha-lipoic Acid Phase 2
42 Antioxidants Phase 2
43 Protective Agents Phase 2
44 Antiviral Agents Phase 2
45 Anti-Infective Agents Phase 2
46
Etoposide phosphate Phase 2 16760419
47 Antimitotic Agents Phase 2
48 Keratolytic Agents Phase 2
49 Nitrogen Mustard Compounds Phase 2
50 Antimetabolites Phase 2

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy Recruiting NCT04589299 Phase 4
3 Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP Recruiting NCT03684018 Phase 4
4 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
6 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
7 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
8 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
10 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT02549170 Phase 3
11 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
12 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
15 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
16 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
17 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
18 Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT05327114 Phase 2, Phase 3 Nipocalimab;Placebo
19 A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) in Japanese Subjects Recruiting NCT05084053 Phase 3 TAK-771
20 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Active, not recruiting NCT02955355 Phase 3
21 Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Not yet recruiting NCT04929236 Phase 3 Panzyga
22 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
23 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo
24 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Completed NCT03864185 Phase 2
25 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT03861481 Phase 2 Rozanolixizumab
26 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
27 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
28 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT04051944 Phase 2 Rozanolixizumab
29 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
30 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
31 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
32 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Completed NCT00278629 Phase 2
33 A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04658472 Phase 2 SAR445088 (IV);SAR445088 (SC)
34 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
35 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04280718 Phase 2
36 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
37 A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT05581199 Phase 2 Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly;Batoclimab 340 mg SC weekly;Placebo
38 Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Not yet recruiting NCT04480450 Phase 2 Rituximab
39 Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT04881682 Phase 2
40 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
41 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
42 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO -CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING IN HEALTHY ADULT MALE PARTICIPANTS AND OPEN-LABEL AFTER SINGLE SUBCUTANEOUS DOSING IN MALE AND FEMALE PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA Recruiting NCT03275740 Phase 1 PF-06755347 intravenous healthy participant;Placebo intravenous healthy participant;PF-06755347 subcutaneous healthy participant;Placebo subcutaneous healthy participant;PF-06755347 subcutaneous ITP
43 The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration Recruiting NCT05584631 Phase 1 Intravenous immune globulin G;Subcutaneous immune globulin G
44 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
45 Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells Unknown status NCT02404298 IVIg
46 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
47 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
48 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Completed NCT03008733
49 Comparison of the Effects of 2 Therapeutic Plasmapheresis Techniques: Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). A Monocentric Prospective Study With a Single-Case Experimental Design Completed NCT04742374 Early Phase 1
50 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769

Search NIH Clinical Center for Polyradiculoneuropathy

Cochrane evidence based reviews: polyradiculoneuropathy

Genetic Tests for Polyradiculoneuropathy

Anatomical Context for Polyradiculoneuropathy

Organs/tissues related to Polyradiculoneuropathy:

MalaCards : Spinal Cord, Dorsal Root Ganglion, Nk Cells, Skin, Tongue, Kidney, Brain

Publications for Polyradiculoneuropathy

Articles related to Polyradiculoneuropathy:

(show top 50) (show all 1790)
# Title Authors PMID Year
1
Recurrent polyradiculoneuropathy and PMP22 defects. 53 62
16323394 2005
2
Assessment of neurological sequelae and new-onset symptoms in the long-term follow-up of paediatric Guillain-Barre syndrome: A longitudinal study from India. 62
36054714 2022
3
[Clinical and neurophysiological patterns of early presenting symptoms in acute onset chronic inflammatory demyelinating polyradiculoneuropathy]. 62
36440746 2022
4
Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy. 62
36401951 2022
5
Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective study. 62
35969369 2022
6
What Is in the Literature. 62
36409336 2022
7
Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy. 62
36368137 2022
8
Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. 62
36190959 2022
9
Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. 62
35837802 2022
10
CIDP prognosis in patients with IVIG treatment-related fluctuations. 62
36330716 2022
11
Acute polyradiculoneuropathy with SARS-CoV2 vaccines: Reply. 62
36056615 2022
12
French recommendations for the management of adult & pediatric chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). 62
36182621 2022
13
Anti-NF155/NF186 IgG4 Antibody Positive Autoimmune Nodopathy. 62
36421911 2022
14
Pathology of Initial Axon Segments in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Related Disorders. 62
36362407 2022
15
Post COVID-19 vaccination Guillain-Barre syndrome: three cases. 62
35240922 2022
16
A Case of Unilateral Recurrent Nerve Palsy with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. 62
34526473 2022
17
Anterior lumbosacral polyradiculoneuropathy following intrathecal methotrexate administration: a case report and literature update. 62
36418611 2022
18
Immune-mediated diseases involving central and peripheral nervous systems. 62
36366904 2022
19
Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study. 62
36028463 2022
20
Chronic inflammatory demyelinating polyradiculoneuropathy concomitant with nephropathy. 62
35737187 2022
21
Emphasis on the Optimal Functional Recovery Through a Structured Inpatient Rehabilitation Program Along With a Home Exercise Regime in an Individual With Miller-Fisher Syndrome: A Case Report. 62
36348871 2022
22
Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion. 62
35876875 2022
23
Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course. 62
35837807 2022
24
Guillain-Barré syndrome with unilateral peripheral facial paralysis in a Chinese child. 62
35993140 2022
25
A Severe Pharyngeal-Sensory-Ataxic Variant of Guillain-Barré Syndrome With Transient Cardiac Dysfunction and a Positive Anti-sulfatide IgM. 62
36277590 2022
26
COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series. 62
35802961 2022
27
Prognostic Significance of Serial Nerve Conduction in GB Syndrome. 62
36352600 2022
28
Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Diabetes: A Case Report. 62
36304380 2022
29
Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. 62
35567759 2022
30
Usefulness and prognostic value of diagnostic tests in patients with possible chronic inflammatory demyelinating polyradiculoneuropathy. 62
35661382 2022
31
Protocol of comparison of the effects of single plasma exchange and double filtration plasmapheresis on peripheral lymphocyte phenotypes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a monocentric prospective study with single-case experimental design. 62
35931957 2022
32
Cyclophosphamide for Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-analysis. 62
35872028 2022
33
[Guillain-Barré syndrome and other autoimmune neurophaties: current therapy]. 62
36054864 2022
34
Rituximab in chronic immune mediated neuropathies: a systematic review. 62
35672205 2022
35
Peripheral neuropathy in sarcoidosis. 62
35585009 2022
36
Are Miller Fisher syndrome and CANDA due to a paranodopathy? 62
35576641 2022
37
Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy. 62
36004023 2022
38
Rare neurological and neuropsychiatric manifestations of scrub typhus: a case series of 10 cases. 62
35907627 2022
39
Original Surgical Treatment and Long-term Follow-up for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Causing a Compressive Cervical Myelopathy: Review of the Literature. 62
35588760 2022
40
A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination. 62
35989967 2022
41
Rituximab Responsive Relapsing-Remitting IgG4 Anticontactin 1 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated With Membranous Nephropathy: A Case Description and Brief Review. 62
35608646 2022
42
Serum thyroid-stimulating hormone is an independent risk factor of recurrent Guillain-Barré syndrome. 62
35342963 2022
43
Nerve ultrasound may help predicting response to immune treatment in chronic inflammatory demyelinating polyradiculoneuropathy. 62
35061135 2022
44
Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Five New Things. 62
35747539 2022
45
Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. 62
35139161 2022
46
Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. 62
35048233 2022
47
Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in Han Chinese. 62
35313093 2022
48
Encephaloradiculoneuropathy: A Rare Manifestation of COVID-19 Infection. 62
35719453 2022
49
[CIDP Refractory to Three Types of Mainstay Treatments: Appropriate Induction Therapy and Evaluation of Therapeutic Effect]. 62
35589640 2022
50
[CIDP Refractory to Three Types of Mainstay Treatments: Differential Diagnosis and Treatment Strategies]. 62
35589641 2022

Variations for Polyradiculoneuropathy

Expression for Polyradiculoneuropathy

Search GEO for disease gene expression data for Polyradiculoneuropathy.

Pathways for Polyradiculoneuropathy

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNFRSF1A IL17A IL10 CXCL12 CCL5 CCL4
2
Show member pathways
13.54 TNFRSF1A IL17A IL10 IFNG CXCL12 CCL5
3
Show member pathways
13.39 TNFRSF1A IL17A IL10 IFNG CXCL12 CCL5
4
Show member pathways
13.31 TNFRSF1A IL17A IL10 CXCL12 CCL5 CCL4
5
Show member pathways
13.16 TNFRSF1A IL17A IL10 IFNG HLA-DRB1 CCL5
6
Show member pathways
13.13 TNFRSF1A IL17A IL10 CXCL12 CCL5 CCL4
7
Show member pathways
12.53 IL17A IL10 IFNG CXCL12 BDNF
8 12.52 NLRP3 IL10 CXCL12 CCL5 CCL4 BDNF
9 12.36 TNFRSF1A IL17A IL10 IFNG CXCL12 CCL5
10 12.04 BDNF IFNG IL10 TNFRSF1A
11
Show member pathways
11.97 CXCL12 CCL5 CCL4 CCL19
12
Show member pathways
11.9 IL17A IL10 IFNG HLA-DRB1 CCL19
13 11.88 MBP IFNG BDNF
14 11.81 PMP22 MPZ MBP
15
Show member pathways
11.8 IL17A IL10 IFNG
16 11.7 IL17A IL10 IFNG
17
Show member pathways
11.69 TNFRSF1A NLRP3 IFNG
18 11.56 CCL19 CXCL12 IFNG IL10
19 11.54 IL17A CXCL12 BDNF
20 11.48 IL10 CCL5 CCL4
21 11.48 TNFRSF1A IL10 IFNG HLA-DRB1
22 11.19 IL10 IFNG HLA-DRB1
23 11.16 PMP22 MPZ MBP
24 11.13 IFNG IL10 IL17A
25 11.12 CCL4 CCL5 IFNG
26 11.07 IL17A IL10 IFNG HLA-DRB1 CXCL12 CCL19
27 11.03 TNFRSF1A IL10 CCL5 CCL4 CCL19
28
Show member pathways
11.01 TNFRSF1A IL10 IFNG CCL4
29 10.81 IFNG CCL4
30 10.7 IL17A IL10 CXCL12 CCL5 CCL4 CCL19

GO Terms for Polyradiculoneuropathy

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.18 TNFRSF1A NLRP3 IL17A IL10 IFNG CXCL12
2 extracellular space GO:0005615 9.64 TNFRSF1A IL17A IL10 IFNG HLA-DRB1 CXCL12
3 compact myelin GO:0043218 9.56 PMP22 MBP
4 myelin sheath GO:0043209 9.43 MBP MPZ PMP2

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.21 TNFRSF1A NLRP3 IL17A CCL5 CCL4 CCL19
2 signal transduction GO:0007165 10.06 BDNF CCL19 CCL4 CCL5 CXCL12 HLA-DRB1
3 cellular response to interleukin-1 GO:0071347 10.01 IL17A CCL5 CCL4 CCL19
4 monocyte chemotaxis GO:0002548 10 CCL5 CCL4 CCL19
5 chemotaxis GO:0006935 9.97 CXCL12 CCL5 CCL4 CCL19
6 myelination GO:0042552 9.95 PMP22 MPZ MBP
7 positive regulation of interleukin-12 production GO:0032735 9.95 CCL19 IFNG IL17A
8 lymphocyte chemotaxis GO:0048247 9.93 CCL5 CCL4 CCL19
9 chemokine-mediated signaling pathway GO:0070098 9.92 CXCL12 CCL5 CCL4 CCL19
10 cellular response to virus GO:0098586 9.91 CCL19 CCL5 IFNG NLRP3
11 negative regulation of dendritic cell apoptotic process GO:2000669 9.86 CXCL12 CCL19
12 positive regulation of interleukin-1 beta production GO:0032731 9.86 NLRP3 IL17A IFNG CCL19
13 positive regulation of interleukin-23 production GO:0032747 9.84 IL17A IFNG
14 positive regulation of natural killer cell chemotaxis GO:2000503 9.81 CCL5 CCL4
15 response to virus GO:0009615 9.65 IFNG CXCL12 CCL5 CCL4 CCL19
16 immune response GO:0006955 9.5 MBP IL17A IL10 IFNG HLA-DRB1 CXCL12

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.76 CXCL12 CCL5 CCL4 CCL19
2 CCR chemokine receptor binding GO:0048020 9.73 CCL5 CCL4 CCL19
3 CCR5 chemokine receptor binding GO:0031730 9.67 CCL5 CCL4
4 CCR1 chemokine receptor binding GO:0031726 9.62 CCL5 CCL4
5 chemokine receptor binding GO:0042379 9.43 CXCL12 CCL5 CCL19
6 cytokine activity GO:0005125 9.36 IL17A IL10 IFNG CXCL12 CCL5 CCL4

Sources for Polyradiculoneuropathy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....